Alvarez RF, Mattos AA, Correa EB, Cotrim HP, Nascimento TV. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol 2005;42(4):256-62. https://www.ncbi.nlm.nih.gov/pubmed/16444382
Biggins SW, Angeli P, Garcia-Tsao G, Gines P, Ling SC, Nadim MK, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74(2):1014-48. https://www.ncbi.nlm.nih.gov/pubmed/33942342
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53(3):397-417. https://www.ncbi.nlm.nih.gov/pubmed/20633946
Komolafe O, Roberts D, Freeman SC, Wilson P, Sutton AJ, Cooper NJ, et al. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2020;1:CD013125. https://www.ncbi.nlm.nih.gov/pubmed/31978256
Lontos S, Shelton E, Angus PW, Vaughan R, Roberts SK, Gordon A, et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014;15(5):260-7. https://www.ncbi.nlm.nih.gov/pubmed/24612987
National Institute for Clinical Excellence (NICE). Cirrhosis in over 16s: assessment and management. London: National Institute for Health and Care Excellence (NICE); 2023. Updated 08 September 2023. Accessed 04 Oct 2023. https://www.nice.org.uk/guidance/ng50
Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122(8):595-8. https://www.ncbi.nlm.nih.gov/pubmed/7887554
